Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (245)	12/14/2000 11:08:25 AM
From: BulbaMan	Respond to of 1784

XENO sells another patent license – this time to Corning. See PR below: Thursday December 14, 8:01 am Eastern Time Press Release Xenometrix Grants Gene Expression Profiling Patent License to Corning Incorporated BOULDER, Colo.--(BW HealthWire)--Dec. 14, 2000--Xenometrix, Inc. (OTCBB:XENO - news) announced that it has granted a worldwide license for gene expression profiling to Corning Incorporated (NYSE:GLW - news), giving Corning access to claims covered in issued U.S. and European patents. The license is non-exclusive and covers the collection of gene expression profiles utilizing all platforms including biochips and high-density microarrays. ``Corning is known worldwide as a technology leader in optics and photonics, glass, and ceramics, and its research products can be found in every life science laboratory. Their platforms will provide a standardization of evolving tools to measure gene expression, and we are pleased to have such an established company using Xenometrix's gene expression profiling technology,'' stated Dr. Pauline Gee, President and Chief Executive Officer. Xenometrix and Corning have agreed to keep both revenue and licensing terms confidential. ``This proprietary gene expression profiling technology from Xenometrix will enable Corning DNA microarrays to be used for many key aspects of gene research and the drug discovery process, including gene discovery, disease target identification, pathway characterization and drug screening,'' stated Thomas R. Hinman, Division Vice President. ``This agreement with Xenometrix further strengthens our portfolio of microarray-related technologies and applications, and enhances Corning's ability to pursue these high-growth opportunities in the life sciences technology industry.'' Xenometrix is a biotechnology company with proprietary gene expression profiling and genotoxicology technologies used to help pharmaceutical, chemical and biotechnology companies accelerate the selection of the most promising drug and chemical leads. For more information, please visit the Xenometrix web site at www.xeno.com. Established in 1851, Corning Incorporated (www.corning.com) creates leading-edge technologies for the fastest-growing markets of the world's economy. Corning manufactures optical fiber, cable and photonic products for the telecommunications industry; and high-performance displays and components for television and other communications-related industries. The company also uses advanced materials to manufacture products for scientific, semiconductor and environmental markets. Corning's revenues in 1999 were $4.7 billion. Except for the historical information contained herein, this release contains forward-looking statements relating to future financial results or business expectations. Business plans may change as circumstances warrant. Actual results could differ materially as a result of risk-related factors over which Xenometrix has no control. Such factors include, but are not limited to, those discussed in ``Business,'' ``Risk Factors,'' and ``Management's Discussion and Analysis of Financial Condition and Results of Operations'' in Xenometrix's Form 10-KSB filed with the Securities and Exchange Commission for the year ended June 30, 2000. Contact: Xenometrix, Inc., Boulder Pauline Gee, 303/447-1773, ext. 105